# GT Biopharma, Inc. (GTBP)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $2M  
**Price:** $0.42 (+1.13%)

> GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapeutics. It leverages proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms to enhance natural killer (NK) cell functions against cancer. Key product candidates include GTB-3650, targeting CD33 on myeloid leukemias in Phase 1 clinical trials; GTB-5550, directed at B7-H3 on advanced solid tumors; and GTB-7550, aimed at lupus and other autoimmune disorders. These therapies address unmet needs in hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as solid tumors and autoimmune conditions. GT Biopharma, Inc. holds a worldwide license from the University of Minnesota for TriKE technology commercialization. Headquartered in San Francisco, California, the company plays a role in advancing NK cell engager therapies within the immuno-oncology market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2020 | — | — | -$7M | -$28M | — |
| 2019 | — | — | $16M | -$39M | — |
| 2017 | — | — | -$136M | -$144M | $-8.60 |
| 2016 | — | — | -$9M | $10M | $119.91 |
| 2015 | $27,000 | $27,000 | -$9M | -$21M | $-8.96 |
| 2014 | $61,000 | $4,000 | -$2M | -$23M | — |
| 2013 | $368,000 | $142,000 | -$793,000 | -$501,000 | — |
| 2012 | $342,000 | $248,000 | -$4M | -$5M | — |
| 2011 | $26,000 | -$22,000 | -$4M | -$4M | — |
| 2010 | $11,000 | -$54,000 | -$2M | -$3M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2020 | $6M | $35M | -$29M | $5M | — |
| 2019 | $396,000 | $20M | -$19M | $28,000 | — |
| 2017 | $254M | $3M | $252M | $576,000 | — |
| 2016 | $25,000 | $19M | -$19M | $19,000 | — |
| 2015 | $54,000 | $51M | -$51M | $47,000 | — |
| 2014 | $888,000 | $30M | -$30M | $855,000 | — |
| 2013 | $147,000 | $6M | -$6M | $43,000 | — |
| 2012 | $226,000 | $7M | -$6M | $123,000 | — |
| 2011 | $129,000 | $5M | -$5M | $92,000 | — |
| 2010 | $185,000 | $6M | -$5M | $54,000 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$13M | — | — |
| 2024 | -$13M | — | — |
| 2023 | -$9M | — | — |
| 2022 | -$15M | — | — |
| 2021 | -$16M | — | — |
| 2020 | -$7M | — | — |
| 2019 | -$4M | — | -$4M |
| 2018 | -$11M | $36,000 | -$11M |
| 2017 | -$5M | $4,000 | -$5M |
| 2016 | -$2M | — | -$2M |
| 2015 | -$5M | $1,000 | -$5M |
| 2014 | -$2M | $6,000 | -$2M |
| 2013 | -$442,000 | — | -$442,000 |
| 2012 | -$987,000 | $2,000 | -$989,000 |
| 2011 | -$963,000 | — | -$963,000 |

Source: [CompaniesByCap](https://companiesbycap.com/company/GTBP)